Patient and disease characteristics
| Characteristic . | Overall population (N = 37) . | No SUD at reinitiation (n = 30) . | SUD at reinitiation (n = 7)∗ . | P value . |
|---|---|---|---|---|
| Median age (IQR), y | 69 (63-77) | 70 (63-77) | 65 (63-78) | .6 |
| Sex, female, n (%) | 20 (54) | 15 (50) | 5 (71) | .4 |
| ECOG performance status, no./total no. (%) | >.9 | |||
| 0 | 4/21 (19) | 4/18 (22) | 0 | |
| 1 | 17/21 (81) | 14/18 (78) | 3/3 (100) | |
| ISS stage, no./total no. (%) | .5 | |||
| I | 10/23 (43) | 8/19 (45) | 2/4 (50) | |
| II | 7/23 (30) | 5/19 (26) | 2/4 (50) | |
| III | 6/23 (26) | 6/19 (32) | 0 | |
| Cytogenetic risk, no./total no. (%) | .8 | |||
| Standard risk | 15/35 (43) | 13/29 (45) | 2/6 (33) | |
| High risk† | 20/35 (57) | 16/29 (55) | 4/6 (67) | |
| Isotype | .2 | |||
| IgG kappa | 21 (57) | 18 (60) | 3 (43) | |
| IgG lambda | 6 (16) | 6 (20) | 0 (0) | |
| IgA kappa | 4 (11) | 2 (6.7) | 2 (29) | |
| IgA lambda | 4 (11) | 3 (10) | 1 (14) | |
| Kappa light chain | 1 (2.7) | 1 (3.3) | 0 (0) | |
| Lambda light chain | 1 (2.7) | 0 | 1 (14) | |
| Extramedullary disease,‡ no./total no. (%) | ||||
| At diagnosis | 13/30 (43) | 11/26 (42) | 2/4 (50) | >.9 |
| Within 3 mo before bispecific | 13/36 (36) | 11/29 (38) | 2/7 (29) | >.9 |
| CNS involvement | 1 (2.7) | 0 (0) | 1∗ (14) | .2 |
| Baseline CrCl of <30 mL/min, no./total no. (%) | 6/36 (17) | 5/29 (17) | 1/7 (14) | >.9 |
| Triple-class refractory, n (%) | 31 (84) | 25 (83) | 6 (86) | >.9 |
| Penta-drug refractory, n (%) | 9 (24) | 7 (23) | 2 (29) | >.9 |
| Median prior lines (range) | 7 (4-9) | 7 (4-9) | 8 (5-9) | .7 |
| Median time from diagnosis to bsAb initiation (IQR), mo | 78 (58-109) | 82 (48-113) | 68 (60-109) | .8 |
| Prior BCMA-directed therapy, n (%) | 16 (43) | 12 (40) | 4 (57) | .4 |
| ADC | 9 (24) | 7 (23) | 2 (29) | >.9 |
| CAR-T | 10 (27) | 7 (23) | 3 (43) | .4 |
| Bispecific | 2 (5) | 2 (7) | 0 (0) | >.9 |
| Prior non-BCMA TCR therapy, n (%) | >.9 | |||
| FcRH5 bsAb | 2 (5.4) | 2 (6.7) | 0 | |
| GPRC5D bsAb | 1 (2.7) | 1 (3.3) | 0 | |
| Current therapy, n (%) | >.9 | |||
| Teclistamab | 29 (78) | 23 (77) | 6∗ (86) | |
| Talquetamab | 8 (22) | 7 (23) | 1∗ (14) |
| Characteristic . | Overall population (N = 37) . | No SUD at reinitiation (n = 30) . | SUD at reinitiation (n = 7)∗ . | P value . |
|---|---|---|---|---|
| Median age (IQR), y | 69 (63-77) | 70 (63-77) | 65 (63-78) | .6 |
| Sex, female, n (%) | 20 (54) | 15 (50) | 5 (71) | .4 |
| ECOG performance status, no./total no. (%) | >.9 | |||
| 0 | 4/21 (19) | 4/18 (22) | 0 | |
| 1 | 17/21 (81) | 14/18 (78) | 3/3 (100) | |
| ISS stage, no./total no. (%) | .5 | |||
| I | 10/23 (43) | 8/19 (45) | 2/4 (50) | |
| II | 7/23 (30) | 5/19 (26) | 2/4 (50) | |
| III | 6/23 (26) | 6/19 (32) | 0 | |
| Cytogenetic risk, no./total no. (%) | .8 | |||
| Standard risk | 15/35 (43) | 13/29 (45) | 2/6 (33) | |
| High risk† | 20/35 (57) | 16/29 (55) | 4/6 (67) | |
| Isotype | .2 | |||
| IgG kappa | 21 (57) | 18 (60) | 3 (43) | |
| IgG lambda | 6 (16) | 6 (20) | 0 (0) | |
| IgA kappa | 4 (11) | 2 (6.7) | 2 (29) | |
| IgA lambda | 4 (11) | 3 (10) | 1 (14) | |
| Kappa light chain | 1 (2.7) | 1 (3.3) | 0 (0) | |
| Lambda light chain | 1 (2.7) | 0 | 1 (14) | |
| Extramedullary disease,‡ no./total no. (%) | ||||
| At diagnosis | 13/30 (43) | 11/26 (42) | 2/4 (50) | >.9 |
| Within 3 mo before bispecific | 13/36 (36) | 11/29 (38) | 2/7 (29) | >.9 |
| CNS involvement | 1 (2.7) | 0 (0) | 1∗ (14) | .2 |
| Baseline CrCl of <30 mL/min, no./total no. (%) | 6/36 (17) | 5/29 (17) | 1/7 (14) | >.9 |
| Triple-class refractory, n (%) | 31 (84) | 25 (83) | 6 (86) | >.9 |
| Penta-drug refractory, n (%) | 9 (24) | 7 (23) | 2 (29) | >.9 |
| Median prior lines (range) | 7 (4-9) | 7 (4-9) | 8 (5-9) | .7 |
| Median time from diagnosis to bsAb initiation (IQR), mo | 78 (58-109) | 82 (48-113) | 68 (60-109) | .8 |
| Prior BCMA-directed therapy, n (%) | 16 (43) | 12 (40) | 4 (57) | .4 |
| ADC | 9 (24) | 7 (23) | 2 (29) | >.9 |
| CAR-T | 10 (27) | 7 (23) | 3 (43) | .4 |
| Bispecific | 2 (5) | 2 (7) | 0 (0) | >.9 |
| Prior non-BCMA TCR therapy, n (%) | >.9 | |||
| FcRH5 bsAb | 2 (5.4) | 2 (6.7) | 0 | |
| GPRC5D bsAb | 1 (2.7) | 1 (3.3) | 0 | |
| Current therapy, n (%) | >.9 | |||
| Teclistamab | 29 (78) | 23 (77) | 6∗ (86) | |
| Talquetamab | 8 (22) | 7 (23) | 1∗ (14) |
ADC, antibody-drug conjugate; BCMA, B-cell maturation antigen; CAR-T, chimeric antigen receptor T cell; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; FcRH5, Fc receptor homolog 5; GPRC5D, G protein–coupled receptor, family C, group 5, member D; IgG/A, immunoglobulin G/A; IQR, interquartile range; ISS, International Staging System; TCR, T-cell redirecting therapy.
Includes 3 patients who reinitiated bsAb with and without SUD at different timepoints.
Include gain/amp 1q, del(17p), t(4:14), t(14;16), and/or t(14;20).
Included soft-tissue plasmacytomas not associated with bone.